Details for Patent: 9,174,975
✉ Email this page to a colleague
Which drugs does patent 9,174,975 protect, and when does it expire?
Patent 9,174,975 protects LATUDA and is included in one NDA.
Protection for LATUDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eleven patent family members in seven countries.
Summary for Patent: 9,174,975
| Title: | Remedy for integration dysfunction syndrome |
| Abstract: | The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)--N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylme- thyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in the method. |
| Inventor(s): | Nakamura; Mitsutaka (Osaka, JP), Ogasa; Masaaki (Osaka, JP), Sami; Shunsuke (Osaka, JP) |
| Assignee: | SUMITOMO DAINIPPON PHARMA CO., LTD (Osaka, JP) |
| Application Number: | 10/525,021 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,174,975 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,174,975
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-003 | Dec 7, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-001 | Oct 28, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-005 | Jul 12, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-002 | Oct 28, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-004 | Apr 26, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,174,975
| PCT Information | |||
| PCT Filed | August 20, 2003 | PCT Application Number: | PCT/JP03/10490 |
| PCT Publication Date: | March 04, 2004 | PCT Publication Number: | WO2004/017973 |
International Family Members for US Patent 9,174,975
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 431147 | ⤷ Sign Up | |||
| Australia | 2003257589 | ⤷ Sign Up | |||
| Germany | 60327634 | ⤷ Sign Up | |||
| European Patent Office | 1535616 | ⤷ Sign Up | |||
| European Patent Office | 1944030 | ⤷ Sign Up | |||
| European Patent Office | 2295061 | ⤷ Sign Up | |||
| Spain | 2326078 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
